POORLY DIFFERENTIATED CHORDOMA

Clinical trials for POORLY DIFFERENTIATED CHORDOMA explained in plain language.

Never miss a new study

Get alerted when new POORLY DIFFERENTIATED CHORDOMA trials appear

Sign up with your email to follow new studies for POORLY DIFFERENTIATED CHORDOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New immune attack on rare, aggressive cancers

Disease control Ongoing

This study is testing a combination of two immunotherapy drugs, tiragolumab and atezolizumab, for children and adults with rare, aggressive cancers that have come back or stopped responding to standard treatments. These cancers are missing specific genes (SMARCB1 or SMARCA4). The…

Matched conditions: POORLY DIFFERENTIATED CHORDOMA

Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 23, 2026 15:15 UTC

POORLY DIFFERENTIATED CHORDOMA

Get alerted when new POORLY DIFFERENTIATED CHORDOMA trials appear

New immune attack on rare, aggressive cancers